TLR3 and neoplasm: The anti-tumor potential of EVs derived from murine DCs loaded with OVA or HOCl-oxidized B16-OVA cells that were matured with poly(I:C) (TLR3 ligand), LPS (TLR4 ligand), and CpG-B oligonucleotide (TLR9 ligand) have been compared in a model of B16-OVA melanoma in vivo (Damo et al., 2015).